Savara (NASDAQ:SVRA) Earns “In-Line” Rating from Evercore ISI

Savara (NASDAQ:SVRA)‘s stock had its “in-line” rating reiterated by equities research analysts at Evercore ISI in a research note issued to investors on Wednesday, MarketBeat.com reports. They currently have a $5.00 price target on the stock, down from their previous price target of $7.00. Evercore ISI’s price target would suggest a potential upside of 56.74% from the stock’s current price.

Several other analysts have also recently commented on the company. JMP Securities restated a “market outperform” rating and set a $9.00 target price on shares of Savara in a report on Tuesday, October 1st. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Savara in a report on Tuesday, October 8th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, Savara has a consensus rating of “Moderate Buy” and a consensus target price of $10.17.

Savara Price Performance

NASDAQ:SVRA opened at $3.19 on Wednesday. The firm has a market cap of $525.08 million, a PE ratio of -7.60 and a beta of 1.02. The company’s 50-day moving average price is $3.93 and its two-hundred day moving average price is $4.21. The company has a quick ratio of 11.31, a current ratio of 11.31 and a debt-to-equity ratio of 0.26. Savara has a 12 month low of $3.09 and a 12 month high of $5.70.

Savara (NASDAQ:SVRA) last announced its earnings results on Tuesday, November 12th. The company reported ($0.11) EPS for the quarter, hitting the consensus estimate of ($0.11). On average, equities analysts anticipate that Savara will post -0.44 EPS for the current fiscal year.

Hedge Funds Weigh In On Savara

Hedge funds have recently added to or reduced their stakes in the company. Verition Fund Management LLC lifted its position in Savara by 83.5% during the 3rd quarter. Verition Fund Management LLC now owns 114,495 shares of the company’s stock valued at $485,000 after purchasing an additional 52,084 shares during the period. Vestal Point Capital LP lifted its holdings in Savara by 24.7% in the third quarter. Vestal Point Capital LP now owns 8,090,000 shares of the company’s stock valued at $34,302,000 after buying an additional 1,600,000 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Savara by 5.1% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 125,815 shares of the company’s stock valued at $533,000 after buying an additional 6,141 shares during the period. MetLife Investment Management LLC boosted its stake in Savara by 28.6% in the third quarter. MetLife Investment Management LLC now owns 66,907 shares of the company’s stock valued at $284,000 after acquiring an additional 14,883 shares during the last quarter. Finally, BNP Paribas Financial Markets grew its holdings in Savara by 258.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 25,693 shares of the company’s stock worth $109,000 after acquiring an additional 18,534 shares during the period. Institutional investors own 87.93% of the company’s stock.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.